Cargando…
P2Y12 Receptor Antagonist, Clopidogrel, Does Not Contribute to Risk of Osteoporotic Fractures in Stroke Patients
Background: Stroke is a leading cause of mortality and morbidity. It is associated with excessive bone loss and risk of fracture in stroke patients is high. The P2Y12R antagonist and platelet inhibitor, clopidogrel, is widely used for secondary prevention after a stroke. However, recent studies have...
Autores principales: | Jørgensen, Niklas R., Schwarz, Peter, Iversen, Helle K., Vestergaard, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699442/ https://www.ncbi.nlm.nih.gov/pubmed/29204116 http://dx.doi.org/10.3389/fphar.2017.00821 |
Ejemplares similares
-
P2Y(12) Receptor Antagonist Clopidogrel Attenuates Lung Inflammation Triggered by Silica Particles
por: Santana, Patricia Teixeira, et al.
Publicado: (2020) -
Thiazide Diuretics and the Incidence of Osteoporotic Fracture: A Systematic Review and Meta-Analysis of Cohort Studies
por: Wang, Jun, et al.
Publicado: (2019) -
Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke
por: Rath, Charlotte Lützhøft, et al.
Publicado: (2020) -
Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial
por: Zhang, Xiaoguang, et al.
Publicado: (2023) -
A health economic analysis of osteoporotic fractures: who carries the burden?
por: Hansen, Louise, et al.
Publicado: (2013)